Novo Nordisk AS (MEX:NOVOBN) Margin of Safety % (DCF FCF Based): -153.90% (As of Jun. 24, 2026)


MEX:NOVOBN Novo Nordisk AS MEX:NOVOBN
79 GF Score
Price MXN810.00
GF Value MXN2,387.36
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS Margin of Safety % (DCF FCF Based)?

Novo Nordisk AS MEX:NOVOBN +3.85% 79 Margin of Safety % (DCF FCF Based) is -153.90% as of Jun. 24, 2026. GuruFocus rates MEX:NOVOBN with a GF Score™ of 79/100 and a GF Value™ of MXN2,387.36 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

As of today (2026-06-24), Novo Nordisk AS's Predictability Rank is 2.5-Stars. Novo Nordisk AS's intrinsic value calculated from the Discounted FCF model is MXN1644.29 and current share price is MXN810.00. Consequently,

Novo Nordisk AS's Margin of Safety % (DCF FCF Based) using Discounted FCF model is -153.90%.

MEX:NOVOBN vs LLY, JNJ, ABBV: Margin of Safety % (DCF FCF Based) Comparison

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Nordisk AS Margin of Safety % (DCF FCF Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's Margin of Safety % (DCF FCF Based) falls into.


MEX:NOVOBN
79GF Score
Novo Nordisk AS MEX:NOVOBN
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novo Nordisk AS Margin of Safety % (DCF FCF Based) Calculation

Novo Nordisk AS's Margin of Safety % (DCF FCF Based) for today is calculated as

Margin of Safety % (DCF FCF Based)=(Intrinsic Value: DCF (FCF Based)-Current Price)/Intrinsic Value: DCF (FCF Based)
=(319.02-810.00)/319.02
=-153.90 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted FCF model with default parameters. The calculation method is the same as Discounted Earnings model except free cash flow are used in the calculation instead of earnings per share.

What does a Margin of Safety % (DCF FCF Based) of -153.90% mean?
Novo Nordisk AS (MEX:NOVOBN) has a Margin of Safety % (DCF FCF Based) of -153.90% as of Jun. 24, 2026. Margin of Safety % (DCF FCF Based) is the percent difference between the current price and the intrinsic DCF FCF price. View historical data on Novo Nordisk AS.
Is Novo Nordisk AS's Margin of Safety % (DCF FCF Based) too high?
Novo Nordisk AS's current Margin of Safety % (DCF FCF Based) is -153.90%. Overall, Novo Nordisk AS has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Margin of Safety % (DCF FCF Based) compare to LLY and JNJ?
Novo Nordisk AS's Margin of Safety % (DCF FCF Based) of -153.90% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Margin of Safety % (DCF FCF Based) for a Drug Manufacturers company?
A good Margin of Safety % (DCF FCF Based) depends on the Drug Manufacturers industry context. However, Margin of Safety % (DCF FCF Based) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Margin of Safety % (DCF FCF Based) mean?
A high Margin of Safety % (DCF FCF Based) can signal that a stock is expensive relative to its fundamentals. Margin of Safety % (DCF FCF Based) is the percent difference between the current price and the intrinsic DCF FCF price. View historical data on Novo Nordisk AS. Novo Nordisk AS's current Margin of Safety % (DCF FCF Based) is -153.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (MEX:NOVOBN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN2,387.36, compared to a current price of MXN810.00 — trading 66.1% below its estimated fair value. The current Margin of Safety % (DCF FCF Based) is -153.90%. Novo Nordisk AS's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Margin of Safety % (DCF FCF Based) calculated?
Margin of Safety % (DCF FCF Based) is calculated from a company's financial statements. For Novo Nordisk AS (MEX:NOVOBN), the current Margin of Safety % (DCF FCF Based) is -153.90% as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novo Nordisk AS (MEX:NOVOBN) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of MXN810.00 is trading 66.1% below its estimated GF Value™ of MXN2,387.36. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for MEX:NOVOBN:

  • Margin of Safety % (DCF FCF Based): -153.90%
  • GF Value™: MXN2,387.36 vs. price of MXN810.00 (66.1% below fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the MEX:NOVOBN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
79GF Score

Get the complete analysis for MEX:NOVOBN

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN810.00
Price
MXN2,387.36
GF Value